Incidence of drug-induced torsades de pointes with intravenous amiodarone
- PMID: 29174246
- PMCID: PMC5717288
- DOI: 10.1016/j.ihj.2017.05.024
Incidence of drug-induced torsades de pointes with intravenous amiodarone
Abstract
Aim: To define the incidence, presentation, and outcomes of drug-induced Torsades de Pointes (TdP) with intravenous (IV) amiodarone.
Methods: From January 2014 to August 2016 a total of 268 patients received IV amiodarone, 142 for ventricular tachycardia, 104 for atrial flutter/fibrillation, and 22 for incessant atrial tachycardia. A uniform dosing of amiodarone to yield 1gm/day was used in all patients.
Results: Four of the 268 patients (M:F 1:3) with mean age of 51.25+9.17years developed pause dependent TdP degenerating to VF, after a mean dose of 690+176.63mg, infused over 12+5.88h. The QTc that was 505+9.02ms at the time of TdP normalized to 433.75+6.13ms 48-72h after stopping amiodarone. There was no immediate or late mortality, and patients are well at 5-10 months of follow-up. None of the patients tested positive for LQTS genes.
Conclusion: The incidence of drug-induced TdP with IV amiodarone is about 1.5%. Risk factors include female sex, left ventricular dysfunction, electrolyte abnormalities, baseline prolonged QTc, concomitant beta-blocker, and digoxin therapy. Amiodarone induced TdP has favorable prognosis if recognized and treated promptly, and these patients should not receive amiodarone by any route in future.
Keywords: Acquired LQT; Amiodarone; Proarrhythmia; Torsades de pointes.
Copyright © 2017 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
Figures
References
-
- Connolly S.J. Evidence based analysis of amiodarone efficacy and safety. Circulation. 1999;100:2025–2034. - PubMed
-
- Scheinman M.M., Levine J.H., Cannom D.S. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation. 1995;92(December (11)):3264–3272. - PubMed
-
- Clemo H.F., Wood M.A., Gilligan D.M., Ellenbogen K.A. Intravenous amiodarone for acute heart with atrial tachyarrhythmias. Am J Cardiol. 1998;81(97):594–598. - PubMed
-
- Kirchhof P., Benussi S., Kotecha D. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(October (38)):2893–2962. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
